Department of Microbiology and Immunology, Inje University College of Medicine, Busan 47392, Republic of Korea.
Biomedical Research Center and Department of Biological Sciences, University of Ulsan, Ulsan 44610, Republic of Korea.
Proc Natl Acad Sci U S A. 2017 Jul 18;114(29):E5881-E5890. doi: 10.1073/pnas.1615280114. Epub 2017 Jul 3.
The lung is a prototypic organ that was evolved to reduce immunopathology during the immune response to potentially hazardous endogenous and exogenous antigens. In this study, we show that donor CD4 T cells transiently induced expression of indoleamine 2,3-dioxygenase (IDO) in lung parenchyma in an IFN-γ-dependent manner early after allogeneic hematopoietic stem cell transplantation (HSCT). Abrogation of host IDO expression by deletion of the IDO gene or the IFN-γ gene in donor T cells or by FK506 treatment resulted in acute lethal pulmonary inflammation known as idiopathic pneumonia syndrome (IPS). Interestingly, IL-6 strongly induced IDO expression in an IFN-γ-independent manner when deacetylation of STAT3 was inhibited. Accordingly, a histone deacetylase inhibitor (HDACi) could reduce IPS in the state where IFN-γ expression was suppressed by FK506. Finally, l-kynurenine produced by lung epithelial cells and alveolar macrophages during IPS progression suppresses the inflammatory activities of lung epithelial cells and CD4 T cells through the aryl hydrocarbon receptor pathway. Taken together, our results reveal that IDO is a critical regulator of acute pulmonary inflammation and that regulation of IDO expression by HDACi may be a therapeutic approach for IPS after HSCT.
肺是一种典型的器官,它的进化是为了在对潜在危险的内源性和外源性抗原的免疫反应中减少免疫病理学。在这项研究中,我们表明,供体 CD4 T 细胞在异基因造血干细胞移植(HSCT)后早期以 IFN-γ依赖性方式短暂诱导肺实质中吲哚胺 2,3-双加氧酶(IDO)的表达。通过缺失供体 T 细胞中的 IDO 基因或 IFN-γ基因,或通过 FK506 处理来阻断宿主 IDO 表达,导致称为特发性肺炎综合征(IPS)的急性致命性肺炎症。有趣的是,当 STAT3 的去乙酰化被抑制时,IL-6 以 IFN-γ非依赖性方式强烈诱导 IDO 表达。因此,在 FK506 抑制 IFN-γ表达的情况下,组蛋白去乙酰化酶抑制剂(HDACi)可以减少 IPS。最后,肺上皮细胞和肺泡巨噬细胞在 IPS 进展过程中产生的 L-犬尿氨酸通过芳基烃受体途径抑制肺上皮细胞和 CD4 T 细胞的炎症活性。总之,我们的结果表明 IDO 是急性肺炎症的关键调节剂,HDACi 对 IDO 表达的调节可能是 HSCT 后 IPS 的一种治疗方法。